Targeted Protein Degradation (TPD), including bifunctional degraders and molecular glue degraders, represents a paradigm shift in small molecule drug discovery. However, challenges remain in successfully discovering new TPD drugs. For example, bifunctional degraders face issues such as unfavorable ADME and physicochemical properties due to their molecular complexity. Regarding molecular glue degraders, the discovery of promising compounds often relies heavily on serendipity.